Atara Biotherapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 05/03/2024
Atara Biotherapeutics Stock Forecast and Price Target
The average target price set lately by three experts for Atara Biotherapeutics to reach by the end of the year is $1.65, which would imply a potential upside of approximately 153.85 percent from the previous closing price if it were to be achieved. This prediction is based on a high estimate of $13.00 and a low estimate of $0.50. Even if you're not interested in ATRA stock, you may be interested in its competitors.
153.85% Upside
Atara Biotherapeutics Fair Value Forecast for 2023 - 2025 - 2030
Atara Biotherapeutics's Price has seen impressive growth In the last four years, rising from $0.00 to $0.00 – a growth of 100.00%. In the next year, analysts believe that Fair Value will reach $0.70 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$160.81 | Buy/Sell | $178.42 | 15.04% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$278.39 | Buy/Sell | $303.65 | 14.77% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$65.33 | Buy/Sell | $87.82 | 22.46% |
| ALXN Stock Forecast | Alexion Pharmaceuticals | - |
0
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$213.51 | Buy/Sell | $299.62 | 35.12% |
Atara Biotherapeutics Revenue Forecast for 2023 - 2025 - 2030
Atara Biotherapeutics's Revenue has seen impressive growth In the last year, rising from $20.34M to $63.57M – a growth of 212.54%. In the following year, 6 experts forecast Atara Biotherapeutics's Revenue will decrease by 49.19%, to $32.30M. For the next seven years, the forecast is for Revenue to grow by 89.38%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$83.80 | Buy/Sell | $111.56 | 31.26% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$53.09 | Buy/Sell | $77.05 | 47.86% |
| VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$75.76 | Buy/Sell | $34.00 | 51.80% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$107.00 | Buy/Sell | $85.71 | 2.80% |
| CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CBAY Stock Forecast | CymaBay Therapeutics | - |
8
|
$32.44 | Buy/Sell | $27.73 | -100.00% |
| IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$12.88 | Buy/Sell | $20.42 | 97.98% |
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
Atara Biotherapeutics EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Atara Biotherapeutics's EBITDA has fallen from $-300.64M to $-268.90M – a 10.56% decrease. Analysts predict that Atara Biotherapeutics's EBITDA will increase in the upcoming year, reaching $-284.77M. This would represent an increase of 5.90%. Professionals believe that By 2030, Atara Biotherapeutics's EBITDA will fall to $-232.06M – a 13.70% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$10.43 | Buy/Sell | $17.90 | 91.75% |
| ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$24.13 | Buy/Sell | $52.00 | 127.93% |
| ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$17.08 | Buy/Sell | $33.78 | 75.64% |
Atara Biotherapeutics EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Atara Biotherapeutics's EBIT has decreased from $-309.05M to $-274.55M – a 11.16% drop. In the following year, 6 experts forecast that Atara Biotherapeutics's EBIT will decrease by 19.51%, to $-220.98M. In 2030, professionals predict that Atara Biotherapeutics's EBIT will decrease by 66.09%, to $-93.10M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$40.86 | Buy/Sell | $63.29 | 88.45% |
| VCEL Stock Forecast | Vericel | Buy |
8
|
$47.88 | Buy/Sell | $42.58 | 14.87% |
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$34.58 | Buy/Sell | $40.00 | 28.69% |
Atara Biotherapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
Atara Biotherapeutics's EPS has seen impressive growth In the last four years, rising from $-4.15 to $0.00 – a growth of 100.00%. In the next year, analysts believe that EPS will reach $-1.67 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ARDX Stock Forecast | Ardelyx | Buy |
11
|
$6.79 | Buy/Sell | $9.94 | 98.82% |
| ADMA Stock Forecast | ADMA Biologics | Buy |
9
|
$6.74 | Buy/Sell | $6.00 | 18.69% |
| DVAX Stock Forecast | Dynavax Technologies | Outperform |
11
|
$11.72 | Buy/Sell | $25.00 | 109.04% |
Site Navigation
.jpg)